Glycerol for acute stroke.

Abstract

BACKGROUND:

Brain oedema is a major cause of early death after stroke. A 10% solution of glycerol is a hyperosmolar agent that is claimed to reduce brain oedema.

OBJECTIVES:

To determine whether I.V. glycerol treatment in acute stroke, either ischaemic or haemorrhagic, influences death rates and functional outcome in the short or long term and whether the treatment is safe.

SEARCH STRATEGY:

The Cochrane Stroke Group Trials Register was searched, conference proceedings were screened and some trialists were personally contacted.

SELECTION CRITERIA:

All completed, randomised and quasi-randomized, controlled, published and unpublished comparisons, evaluating clinical outcome in which intravenous (I.V.) glycerol treatment was initiated within the first days after stroke onset.

DATA COLLECTION AND ANALYSIS:

Two reviewers independently applied the inclusion criteria, assessed the trial quality and extracted data and this was checked with all co-reviewers. Death from all causes, functional outcome and adverse effects were analysed.

MAIN RESULTS:

Eleven completed, randomised trials comparing I.V. glycerol and control were considered. Analysis of death during the scheduled treatment period for acute ischaemic and/or haemorrhagic stroke was possible in ten trials where 482 glycerol treated patients were compared with 463 control patients. Glycerol was associated with a non-significant reduction in the odds of death within the scheduled treatment period (OR 0.78, 95% Confidence Intervals 0.58 - 1.06). Among patients with definite or probable ischaemic stroke, glycerol was associated with a significant reduction in the odds of death during the scheduled treatment period (odds ratio 0.65, 95% CI 0.44-0.97). However, at the end of the scheduled follow up period, there was no significant difference in the odds of death (odds ratio 0.98, 95% CI 0.73-1.31). Functional outcome was reported in only two studies but there were non-significantly more patients who had a good outcome at the end of scheduled follow up (odds ratio 0.73, 95% CI 0.37-1.42). Haemolysis seems to be the only relevant adverse effect of glycerol treatment.

REVIEWER'S CONCLUSIONS:

This systematic review suggests a favourable effect of glycerol treatment on short term survival in patients with probable or definite ischaemic stroke but the magnitude of the treatment effect may be minimal (as low as a 3% reduction in odds). Due to the relatively small number of patients and that the trials have been performed in the pre-CT era, the results must be interpreted cautiously. The lack of evidence of benefit in long term survival does not support the routine or selective use of glycerol treatment in patients with acute stroke.

• Authors: E Righetti, M G Celani, T Cantisani, R Sterzi, G Boysen, S Ricci
• Journal: The Cochrane database of systematic reviews (Cochrane Database Syst Rev) Issue 4 Pg. CD000096 ( 2000) ISSN: 1469-493X [Electronic] England
• PMID: 11034673 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Glycerol

Topics

• Brain Edema (etiology, prevention & control)
• Brain Ischemia (drug therapy)
• Glycerol (therapeutic use)
• Humans
• Randomized Controlled Trials as Topic
• Stroke (complications, drug therapy)